A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases

Area of Science:

• Biochemistry
• Pharmacology
• Cardiology

Background:

• Cardiovascular diseases are a leading cause of death globally.
• Elevated Low-Density Lipoprotein-Cholesterol (LDL-C) is a primary risk factor.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL receptor degradation, impacting LDL-C levels.

Purpose of the Study:

• To review the chemistry, pharmacokinetics, and pharmacodynamics of PCSK9 inhibitors.
• To discuss the clinical effects of PCSK9 inhibitors in managing cholesterol levels.

Main Methods:

• Review of scientific literature on PCSK9 inhibitors.
• Analysis of pharmacokinetic and pharmacodynamic data.
• Evaluation of clinical trial outcomes for alirocumab and evolocumab.

Main Results:

• PCSK9 inhibitors block PCSK9, increasing LDL receptor recycling.
• This mechanism significantly reduces serum LDL-C levels.
• Alirocumab and evolocumab are approved treatments for hypercholesterolemia.

Conclusions:

• PCSK9 inhibitors represent a novel therapeutic class for lowering LDL-C.
• These agents effectively reduce a key risk factor for cardiovascular disease.
• Further research may elucidate long-term clinical benefits and applications.